• Akiko Otake, Kiyoshi Yoshino, Yutaka Ueda, Kenjiro Sawada, Seiji Mabuchi, Toshihiro Kimura, Eiji Kobayashi, Aki Isobe, Tomomi Egawa-Takata, Shinya Matsuzaki, Masami Fujita, and Tadashi Kimura.
• Department of Obstetrics and Gynecology, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan.
• Anticancer Res. 2015 Jan 1;35(1):359-63.

AimThe present study aimed at evaluating the usefulness and adverse effects of duloxetine treatment for paclitaxel-induced peripheral neuropathy in gynecological cancer patients.Patients And MethodsMedical records of gynecological cancer patients treated with duloxetine were retrospectively studied to evaluate the drug's efficacy for paclitaxel-induced peripheral neuropathy.ResultsRESULTS from 25 patients showed that an improved response was observed in 14 (56%). By univariate and multivariate analysis, the patient's age, tumor origin, regimen of chemotherapy, accumulated doses of paclitaxel or carboplatin, previous medication, maintenance dosage and timing of treatment with duloxetine were found not to be associated with the effectiveness of duloxetine treatment. Adverse effects with duloxetine were mild and well-tolerated.ConclusionAs an option, duloxetine can be effectively used for paclitaxel-induced peripheral neuropathy in patients with gynecological cancers, irrespective of patients' age, origin of the tumor, regimen of chemotherapy, or previous medication.Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

27 keywords...

hide…